Janssen announces first data centres for haematology networkJanssen has announced the first two data centres to join its HONEUR (Haematology Outcomes Network in Europe) collaborative Share XJanssen announces first data centres for haematology networkhttps://pharmaphorum.com/news/janssen-announces-first-data-centres-for-haematology-network/
Drug middlemen point finger at pharma in US pricing debateThe so-called ‘middlemen’ in the US pharma supply chain have blamed big pharma for skyrocketing drug prices in Share XDrug middlemen point finger at pharma in US pricing debatehttps://pharmaphorum.com/news/drug-middlemen-point-finger-at-pharma-in-us-pricing-debate/
Health secretary urged to investigate epilepsy medicine shortageHealth Secretary Matt Hancock has been urged to immediately review the epilepsy medicine supply chain, after ongoing problems Share XHealth secretary urged to investigate epilepsy medicine shortagehttps://pharmaphorum.com/news/health-secretary-urged-to-investigate-epilepsy-medicine-shortage/
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerThe European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced Share XAZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-eu-nod-for-hard-to-treat-breast-cancer/
At long last, Amgen/UCB score FDA okay for EvenityAmgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down Share XAt long last, Amgen/UCB score FDA okay for Evenityhttps://pharmaphorum.com/news/at-long-last-amgen-ucb-score-fda-okay-for-evenity/
Novartis sues as Amgen tries to cancel migraine tie-upNovartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, Share XNovartis sues as Amgen tries to cancel migraine tie-uphttps://pharmaphorum.com/news/novartis-sues-as-amgen-tries-to-cancel-migraine-tie-up/
Fusion raises $105m for radiopharmaceutical trialsRadiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to Share XFusion raises $105m for radiopharmaceutical trialshttps://pharmaphorum.com/news/fusion-raises-105m-towards-radiopharmaceutical-trials/
‘Obs’ device gets backing in UK digital health funding roundThe UK government has handed out a further tranche of cash to digital health projects exploring artificial intelligence, Share X‘Obs’ device gets backing in UK digital health funding roundhttps://pharmaphorum.com/news/obs-device-gets-backing-in-uk-digital-health-funding-round/
Merck’s oral MS drug finally gets FDA okayMerck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after Share XMerck’s oral MS drug finally gets FDA okayhttps://pharmaphorum.com/news/mercks-oral-ms-drug-finally-gets-fda-okay/
